PROTAC GSK3 degrader-1
PROTAC GSK3 degrader-1 is a potent, blood-brain barrier-permeable GSK3 PROTAC degrader, with a DC50 of 1.4 nM against GSK3β. PROTAC GSK3 degrader-1 exerts equally potent degradation activity against both GSK3α and GSK3β. It inhibits the phosphorylation of CRMP2, PRKAA1 and Tau, and stabilizes β-catenin. PROTAC GSK3 degrader-1 can be used in the research of Alzheimer's disease and Parkinson's disease.
(Pink: GSK-3 ligand (HY-185635); Blue: Cereblon ligand (HY-W1137162); Black: linker).
For research use only. We do not sell to patients.
- Formula: C47H46N16O4
- Molecular Weight:898.97
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
GSK-3β 1.4 nM (DC50) |
GSK-3α |
In Vitro
PROTAC GSK3 degrader-1 (Compound KH1) (10 nM; 2 h) almost completely degrades GSK3α and GSK3β in HEK293 cells, and this degradation depends on the ubiquitin-proteasome system and binding to GSK3[1].
PROTAC GSK3 degrader-1 (0.1-100 nM; 24 h) degrades GSK3β in differentiated SH-SY5Y neuroblastoma cells, with an onset concentration of 0.1 nM; at higher concentrations, it reduces phosphorylated CRMP2 levels and stabilizes β-catenin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Differentiated SH-SY5Y neuroblastoma cells
-
Concentration:0.1, 1, 10 and 100 nM
-
Incubation Time:24 h
-
Result:Degraded GSK3β at concentrations between 0.1 and 10 nM.
Reduced phospho-CRMP2 levels concurrently with GSK3β degradation.
Stabilized β-catenin most evident at the highest tested concentration of 100 nM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (female)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; single bolus dose
-
Result:Reduced brain GSK3β levels to ~60% of control levels.
Reduced liver GSK3β levels to ~20% of control levels.
Achieved high proteome-wide specificity for GSK3β removal in liver tissue.
Reduced phosphorylation of GSK3α (Ser21) and AMPK alpha sub-unit (PRKAA1) in liver tissue.
Chemical Information
-
Molecular Weight 898.97
-
Formula C47H46N16O4
-
SMILES
O=C(C1=CC=NN2C1=NC(C3=CC=C(N4N=NC(C5=NC=C(CN6CCN(CC7=CC8=C(C=C7)C(N(C(N9)=O)CCC9=O)=NN8C)CC6)C=C5)=C4)C=C3)=C2)NC%10=C(N%11CCOCC%11)C=CN=C%10
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)